X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CX-904 is an investigational, masked, conditionally activated PROBODY T-cell engager designed to target the EGFR on cancer cells and the CD3 receptor on T cells. It is being evaluated for the treatment of advanced pancreatic cancer.
Lead Product(s): CX-904
Therapeutic Area: Oncology Product Name: CX-904
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
The collaboration aims for the development of CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).
Lead Product(s): CX-801,Pembrolizumab
Therapeutic Area: Oncology Product Name: CX-801
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 06, 2024
Details:
CX-2051 is a masked PROBODY antibody drug conjugate directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers.
Lead Product(s): CX-2051
Therapeutic Area: Oncology Product Name: CX-2051
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
The collaboration is to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets for the treatment of cancer. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration April 03, 2024
Details:
The clinical candidate is the first PROBODY® T-cell engaging bispecific (TCB) molecule under the alliance between CytomX and Astellas to progress into a GLP toxicology study.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration evolves to ongoing research programs, including multiple T-cell engagers. The anti-CTLA-4 PROBODY BMS-986288, a Probody version of the anti-CTLA-4 antibody ipilimumab, will not be further advanced following a recent BMS internal portfolio review.
Lead Product(s): BMS-986288,Nivolumab
Therapeutic Area: Oncology Product Name: BMS-986288
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $2,000.0 million Upfront Cash: $200.0 million
Deal Type: Collaboration March 12, 2024
Details:
CX-2051 is an EpCAM-directed ADC, and CX-801, a dually-masked version of interferon-alpha 2b. Its IND application has been cleared by USFDA for the treatment of EpCAM expressed colorectal cancer.
Lead Product(s): CX-2051
Therapeutic Area: Oncology Product Name: CX-2051
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
The net funding will be used in the development of CX-2029, an investigational a conditionally activated antibody-drug conjugate directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors.
Lead Product(s): CX-2029
Therapeutic Area: Oncology Product Name: CX-2029
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners L.P.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 30, 2023
Details:
The collaboration is to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets for the treatment of cancer. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration January 26, 2023
Details:
Moderna’s global impact has shown the enormous power of mRNA and working closely with the newest collaborator to bring novel, mRNA-based conditionally activated therapeutics to patients with unmet medical needs.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: $1,235.0 million Upfront Cash: $35.0 million
Deal Type: Collaboration January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
